Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2019-04-17 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings
2019-04-17 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2019
Earnings Release Classification · 95% confidence The document is a short company announcement (under 5,000 characters of core content) regarding the net sales of a specific product (DARZALEX) for the first quarter of 2019. It explicitly labels itself as a 'Company Announcement' and includes an 'Attachment' link at the bottom, which is a hallmark of a Report Publication Announcement (RPA) according to the provided rules. It is not a full quarterly report (IR) or earnings release (ER) in the sense of a comprehensive financial statement, but rather a notification of specific sales figures and the availability of further information. Q1 2019
2019-04-16 English
Earnings Release 2019
Earnings Release Classification · 100% confidence The document is titled "Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2019" and provides specific financial figures (Net sales of USD 629 million for Q1 2019) related to a product's performance for a defined period. This structure—announcing key financial results for a specific quarter—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim/Quarterly Report (IR), as it focuses only on the net sales announcement and related product information, rather than a full set of financial statements and management discussion and analysis typical of IR or 10-K. It is too specific to be a general Regulatory Filing (RNS) and is not a transcript (CT) or a presentation (IP). Q1 2019
2019-04-16 English
Regulatory Filings 2019
Regulatory Filings
2019-04-11 English
Director's Dealing 2019
Director's Dealing Classification · 100% confidence The document is titled "Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them." It details specific transactions (Sale of shares) made by individuals holding positions like 'Member of the Board of Directors' and 'President & Chief Executive Officer' of the issuer 'Genmab A/S'. This structure and content precisely match the definition of a Director's Dealing report, which tracks insider trades by executives and directors.
2019-04-04 English
Genmab Announces Phase III Study Exploring Daratumumab as Maintenance Treatment in Newly Diagnosed Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding the initiation of a Phase III clinical trial for a drug (daratumumab). It provides details on the study design, the partnership with Janssen, and background information on the disease and the drug. It does not fit into financial reporting categories like 10-K or IR, nor is it a simple report publication notice (RPA). As it is a general regulatory/corporate announcement regarding business operations and clinical developments, it falls under the 'Regulatory Filings' (RNS) category.
2019-04-03 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.